$2.85
0.04[1.42%]
Last update: 9:52AM Get Real Time Here
Arbutus Biopharma
(NASDAQ:ABUS)Arbutus Biopharma Stock (NASDAQ:ABUS), Analyst Ratings, Price Targets, Predictions
Arbutus Biopharma Corp has a consensus price target of $5.4, established from looking at the 24 latest analyst ratings. The last 3 analyst ratings were released from Chardan Capital, JMP Securities, and Chardan Capital on May 3, 2024, April 4, 2024, and March 1, 2024. With an average price target of $4 between Chardan Capital, JMP Securities, and Chardan Capital, there's an implied 40.35% upside for Arbutus Biopharma Corp from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Chardan Capital
JMP Securities
HC Wainwright & Co.
Jefferies
JMP Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Arbutus Biopharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/03/2024 | Buy Now | 40.35% | Chardan Capital | Keay Nakae | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 04/04/2024 | Buy Now | 40.35% | JMP Securities | Roy Buchanan | → $4 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/01/2024 | Buy Now | 40.35% | Chardan Capital | Keay Nakae | → $4 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 75.44% | HC Wainwright & Co. | Ed Arce | $6 → $5 | Maintains | Buy | Get Alert |
| 09/12/2023 | Buy Now | 110.53% | HC Wainwright & Co. | Ed Arce | → $6 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | Buy Now | 110.53% | HC Wainwright & Co. | Ed Arce | → $6 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | Buy Now | 110.53% | Chardan Capital | Keay Nakae | → $6 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | 110.53% | HC Wainwright & Co. | Ed Arce | → $6 | Reiterates | Buy → Buy | Get Alert |
| 07/06/2023 | Buy Now | 110.53% | JMP Securities | Roy Buchanan | → $6 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/22/2023 | Buy Now | 110.53% | HC Wainwright & Co. | Ed Arce | → $6 | Reiterates | Buy → Buy | Get Alert |
| 06/22/2023 | Buy Now | 110.53% | Chardan Capital | Keay Nakae | → $6 | Reiterates | Buy → Buy | Get Alert |
| 05/05/2023 | Buy Now | 110.53% | HC Wainwright & Co. | Ed Arce | → $6 | Reiterates | → Buy | Get Alert |
| 04/28/2023 | Buy Now | 110.53% | HC Wainwright & Co. | Ed Arce | → $6 | Reiterates | → Buy | Get Alert |
| 04/05/2023 | Buy Now | 110.53% | HC Wainwright & Co. | Ed Arce | → $6 | Reiterates | → Buy | Get Alert |
| 03/29/2023 | Buy Now | 110.53% | JMP Securities | Roy Buchanan | → $6 | Reiterates | → Market Outperform | Get Alert |
| 03/20/2023 | Buy Now | 110.53% | HC Wainwright & Co. | Ed Arce | → $6 | Reiterates | → Buy | Get Alert |
| 03/03/2023 | Buy Now | 110.53% | Chardan Capital | Keay Nakae | → $6 | Reiterates | → Buy | Get Alert |
| 03/03/2023 | Buy Now | 110.53% | HC Wainwright & Co. | Ed Arce | → $6 | Maintains | Buy | Get Alert |
| 11/10/2022 | Buy Now | 110.53% | HC Wainwright & Co. | Ed Arce | $7.5 → $6 | Maintains | Buy | Get Alert |
| 06/28/2022 | Buy Now | 215.79% | JMP Securities | Roy Buchanan | $10 → $9 | Maintains | Market Outperform | Get Alert |
| 03/14/2022 | Buy Now | 198.25% | HC Wainwright & Co. | Ed Arce | $8 → $8.5 | Maintains | Buy | Get Alert |
| 03/04/2022 | Buy Now | 110.53% | Chardan Capital | Keay Nakae | $5.5 → $6 | Maintains | Buy | Get Alert |
| 02/02/2022 | Buy Now | 75.44% | Jefferies | Dennis Ding | $4 → $5 | Upgrade | Hold → Buy | Get Alert |
| 11/08/2021 | Buy Now | 215.79% | JMP Securities | Jason Butler | — | Maintains | Market Outperform | Get Alert |
FAQ
What is the target price for Arbutus Biopharma (ABUS)?
The latest price target for Arbutus Biopharma (NASDAQ: ABUS) was reported by Chardan Capital on May 3, 2024. The analyst firm set a price target for $4.00 expecting ABUS to rise to within 12 months (a possible 40.35% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Arbutus Biopharma (ABUS)?
The latest analyst rating for Arbutus Biopharma (NASDAQ: ABUS) was provided by Chardan Capital, and Arbutus Biopharma reiterated their buy rating.
When was the last upgrade for Arbutus Biopharma (ABUS)?
The last upgrade for Arbutus Biopharma Corp happened on February 2, 2022 when Jefferies raised their price target to $5. Jefferies previously had a hold for Arbutus Biopharma Corp.
When was the last downgrade for Arbutus Biopharma (ABUS)?
There is no last downgrade for Arbutus Biopharma.
When is the next analyst rating going to be posted or updated for Arbutus Biopharma (ABUS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arbutus Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arbutus Biopharma was filed on May 3, 2024 so you should expect the next rating to be made available sometime around May 3, 2025.
Is the Analyst Rating Arbutus Biopharma (ABUS) correct?
While ratings are subjective and will change, the latest Arbutus Biopharma (ABUS) rating was a reiterated with a price target of $4.00 to $4.00. The current price Arbutus Biopharma (ABUS) is trading at is $2.85, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.